🚀 VC round data is live in beta, check it out!
Opthea Valuation Multiples
Discover revenue and EBITDA valuation multiples for Opthea and similar public comparables like Strategic Partners, Newbury Pharmaceuticals, Genetic Technologies, RA Williams Distributors and more.
Opthea Overview
About Opthea
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.
Founded
1984
HQ
Employees
34
Website
Sectors
Financials (LTM)
EV
$30M
Opthea Financials
Opthea reported last 12-month revenue of $25K.
In the same LTM period, Opthea generated had net loss of ($163M).
Revenue (LTM)
Opthea P&L
In the most recent fiscal year, Opthea reported revenue of $25K and EBITDA of ($123M).
Opthea expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $25K | XXX | $25K | XXX | XXX | XXX |
| EBITDA | — | XXX | ($123M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (492760%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (609248%) | XXX | XXX | XXX |
| Net Profit | ($163M) | XXX | ($163M) | XXX | XXX | XXX |
| Net Margin | (651164%) | XXX | (651164%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Opthea Stock Performance
Opthea has current market cap of $4M, and enterprise value of $30M.
Market Cap Evolution
Opthea's stock price is $0.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $30M | $4M | 0.0% | XXX | XXX | XXX | $-0.95 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOpthea Valuation Multiples
Opthea trades at 1182.2x EV/Revenue multiple, and (0.2x) EV/EBITDA.
EV / Revenue (LTM)
Opthea Financial Valuation Multiples
As of April 19, 2026, Opthea has market cap of $4M and EV of $30M.
Equity research analysts estimate Opthea's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Opthea has a P/E ratio of (0.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4M | XXX | $4M | XXX | XXX | XXX |
| EV (current) | $30M | XXX | $30M | XXX | XXX | XXX |
| EV/Revenue | 1182.2x | XXX | 1182.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.2x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (0.2x) | XXX | XXX | XXX |
| P/E | (0.0x) | XXX | (0.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Opthea Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Opthea Margins & Growth Rates
Opthea's revenue in the last fiscal year declined by (67%).
Opthea's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $4.5M for the same period.
Opthea Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (67%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (492760%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (24%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $4.5M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 82148% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 507328% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 609348% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Opthea Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Opthea | XXX | XXX | XXX | XXX | XXX | XXX |
| Strategic Partners | XXX | XXX | XXX | XXX | XXX | XXX |
| Newbury Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Genetic Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| RA Williams Distributors | XXX | XXX | XXX | XXX | XXX | XXX |
| Geovax Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Opthea M&A Activity
Opthea acquired XXX companies to date.
Last acquisition by Opthea was on XXXXXXXX, XXXXX. Opthea acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Opthea
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialOpthea Investment Activity
Opthea invested in XXX companies to date.
Opthea made its latest investment on XXXXXXXX, XXXXX. Opthea invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Opthea
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Opthea
| When was Opthea founded? | Opthea was founded in 1984. |
| Where is Opthea headquartered? | Opthea is headquartered in Australia. |
| How many employees does Opthea have? | As of today, Opthea has over 34 employees. |
| Who is the CEO of Opthea? | Opthea's CEO is Jeremy M. Levin. |
| Is Opthea publicly listed? | Yes, Opthea is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of Opthea? | Opthea trades under OPTEY ticker. |
| When did Opthea go public? | Opthea went public in 1991. |
| Who are competitors of Opthea? | Opthea main competitors are Strategic Partners, Newbury Pharmaceuticals, Genetic Technologies, RA Williams Distributors. |
| What is the current market cap of Opthea? | Opthea's current market cap is $4M. |
| What is the current revenue of Opthea? | Opthea's last 12 months revenue is $25K. |
| What is the current EV/Revenue multiple of Opthea? | Current revenue multiple of Opthea is 1182.2x. |
| Is Opthea profitable? | No, Opthea is not profitable. |
| What is the current net income of Opthea? | Opthea's last 12 months net income is ($163M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.